Grail vs Exagen
GRAL and XGN side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GRAL and XGN compare
Grail is the larger company, worth 52 times as much as Exagen ($5.2B against $100M).
Grail grew revenue faster over the last twelve months (17.5% versus 13.7% for Exagen).
Exagen keeps more of each dollar of sales as profit, with a net margin of −25.1% compared with −244% at Grail.
Grail scores higher on the StockData Score (10 against 4 for Exagen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GRAL | XGN |
|---|---|---|
| Size and price | ||
| Market cap | $5.2B | $100M |
| Share price | $115.89 | $4.13 |
| Change, 1 year | 36.7% | −56.9% |
| Change, 5 years | – | −65.9% |
| Beta (5Y) | 2.49 | 1.18 |
| Employees | 910 | 220 |
| StockData Score | ||
| Total score | 10 (better) | 4 |
| Valuation score | 1 (better) | 0 |
| Growth score | 2 | 2 |
| Performance score | 1 | 1 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 31.1× | 1.4× (better) |
| P/B | 2.1× (better) | 7.3× |
| FCF yield | −6.0% (better) | −13.0% |
| Fair value | – | $3.60 |
| Margin of safety | – | −14.7% |
| Growth | ||
| Revenue growth (TTM) | 17.5% (better) | 13.7% |
| Revenue growth, 5Y average | – | 9.7% |
| Profitability | ||
| Gross margin | – | 58.7% |
| Operating margin | −347% | −20.1% (better) |
| Net margin | −244% | −25.1% (better) |
| FCF margin | −187% | −18.0% (better) |
| Return on equity | −17.3% (better) | −114% |
| Return on invested capital | −27.1% (better) | −167% |
| Financial health | ||
| Debt / equity | 0.00 | 1.66 (better) |
| Interest coverage | – | −2.9× |
| Current ratio | 8.93 (better) | 3.46 |
| Altman Z-score | 5.51 (better) | −5.71 |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 87.6% | 34.1% |
| Held by insiders | 11.0% | 29.2% |
| Insider net buying, 12 months | −$38.0M | −$22.9K (better) |
| Short interest, % of float | 20.1% | 4.2% |
Go deeper
- GRAL stock overview
- GRAL income statement
- GRAL valuation and score
- XGN stock overview
- XGN income statement
- XGN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.